CAMBRIDGE - Helicos BioSciences Corp., a genetic analysis instrument company, has taken itself off the auction block.
In September, the company said it had hired Thomas Weisel Partners to evaluate strategic alternatives. Those options ranged from an outright sale to options such as joint ventures or partnerships with other gene-sequencing companies.
“Based on the company’s improving standalone prospects and its current market valuation, the board of directors has decided to disengage from discussions involving a potential sale of the company at the current time,’’ Helicos said Monday.
The company said it continues to work with Thomas Weisel as a financial adviser.
“We are seeing a growing number of novel discoveries resulting from the Helicos Genetic Analysis System’s unique capabilities and have seen an increased interest in clinical applications for which the Helicos system is uniquely suited,’’ chief executive Ron Lowy said.
